Skip to main content
  • Poster presentation
  • Open access
  • Published:

PReS-FINAL-2224: Canakinumab treatment regimens in CAPS-patients

Introduction

Canakinumab is a recombinant monoclonal fully human antibody against Interleukin-1β and approved for the treatment of CAPS in many countries including Europe and the US. Current dose recommendations are 150 mg (body weight >40 kg) respectively 2 mg/kg body weight (15 to 40 kg) every 8 weeks but yield insufficient response in some individuals, especially in children and patients with severe phenotypes [1].

Objectives

In this study we analyzed the response to daily practice (in contrast to trial condition) canakinumab treatment regimens in CAPS patients with focus on age, mutation and clinical presentation and the necessity and effect of dose adjustment.

Methods

An observational national multicenter study was conducted. CAPS patients were included if they received at least two doses of canakinumab. Data included information regarding demographics, treatment, clinical disease activity and inflammatory markers (including SAA, CRP, ESR, IL-6). Response to treatment was assessed using CAPS-disease activity scores, CRP and/or SAA levels.

Results

A cohort of 68 patients with CAPS was analyzed. Median age was 25.4 years (range 22 months to 73 years). When treatment was initiated, 27 patients had been younger than 18 years. The most frequent mutations were R260W, A439V, E311K, V198M, Q703K and most patients showed MWS or FCAS/MWS phenotype (3 patients with NOMID, 4 with MWS/NOMID). The median treatment duration was 855 days (range: 28-1973 days). In 39 patients (57%) full response was sustained until the next scheduled drug application (34% (23 patients) partial remission). With standard treatment 21 patients (31%) achieved full response. In 30 patients (44%) canakinumab dose and/or application interval was increased above the standard regimen (2/3 NOMID, 3/4 MWS/NOMID). Neither laboratory parameters nor clinical disease activity at the beginning of treatment were able to predict the necessity to adjust treatment regimen. Two serious adverse events were reported (severe infection, osteonecrosis), mild and moderate adverse events were mostly upper respiratory tract infections but almost no injection site reactions.

Conclusion

Most CAPS patients achieve full remission with canakinumab. However, almost 50% of patients, particularly children, require dose adjustment. Full remission by dose increase was achieved without an increased rate of adverse events. Individual adjustment of therapy should be performed as needed as predictive parameters are lacking.

Disclosure of interest

F. Hofer: None declared, T. Endres: None declared, B. Kortus-Götze: None declared, N. Blank: None declared, E. Weißbarth-Riedel: None declared, C. Schütz: None declared, T. Kallinich: None declared, K. Krause: None declared, C. Rietschel: None declared, G. Horneff: None declared, J. Kuemmerle-Deschner Grant/Research Support from: NOVARTIS, Consultant for: NOVARTIS, SOBI.

References

  1. Kuemmerle-Deschner JB et al.: Two years results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis. 2011, 70: 2095-2102. 10.1136/ard.2011.152728.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( https://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Cite this article

Hofer, F., Endres, T., Kortus-Götze, B. et al. PReS-FINAL-2224: Canakinumab treatment regimens in CAPS-patients. Pediatr Rheumatol 11 (Suppl 2), P214 (2013). https://doi.org/10.1186/1546-0096-11-S2-P214

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/1546-0096-11-S2-P214

Keywords